Hematopoietic System

Haschek and Rousseaux's Handbook of Toxicologic Pathology

Volumn , Issue , 2013, Pages 1863-1933

  Ramaiah, Lila ^a   Bounous, Denise I ^b   Elmore, Susan A ^c  

^a Huntingdon Life Sciences New Jersey   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Bone marrow; Erythroid; Hematopoiesis; Hematopoietic stem cell; Hematotoxicity; Megakaryocyte; Myeloid

Indexed keywords

EID: 84884115291     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415759-0.00050-9     Document Type: Chapter

References (91)

1. Cumano A., Godin I. Ontogeny of the Hematopoietic System. Annu. Rev. Immunol. 2007, 25(1):745-785.
2. Galíndez E.J., Aggio M.C. The hemopoietic system: a phylogenetic approach. Histol. Histopathol. 1997, 12:823-826.
3. Glomski C.A., Tamburlin J. The phylogenetic odyssey of the erythrocyte. I. Hemoglobin: the universal respiratory pigment. Histol. Histopathol. 1989, 4:509-514.
4. Glomski C.A., Tamburlin J. The phylogenetic odyssey of the erythrocyte. II. The early or invertebrate prototypes. Histol. Histopathol. 1990, 5:513-525.
5. Litman G.W., Cannon J.P., Dishaw L.J. Reconstructing immune phylogeny: new perspectives. Nat. Rev. Immunol. 2005, 5(11):866-879.
6. Long C.A. Evolution of function and form in camelid erythrocytes. BIO'07: Proceedings of the 3rd WSEAS International Conference on Cellular and Molecular Biology, 18-24 2007, Greece, Athens.
7. Tavian M., Peault B. Embryonic development of the human hematopoietic system. Int. J. Dev. Biol. 2005, 49(2-3):243-250.
8. Tavian M., Biasch K., Sinka L., Vallet J., Peault B. Embryonic origin of human hematopoiesis. Int. J. Dev. Biol. 2010, 54(6-7):1061-1065.
9. Terwilliger N.B. Functional adaptations of oxygen-transport proteins. J. Exper. Biol. 1998, 201(Pt 8):1085-1098.
10. Weber R.E., Vinogradov S.N. Nonvertebrate hemoglobins: functions and molecular adaptations. Physiol. Rev. 2001, 81(2):569-628.
11. Weiss D.J., Wardrop K.J. Schalm's Veterinary Hematology 2011, Wiley-Blackwell, New York, NY.
12. Cesta M. Normal structure, function, and histology of the spleen. Toxicol. Pathol. 2006, 34:455-465.
13. Fibach E. Involvement of Phosphatases in Proliferation, Maturation, and Hemoglobinization of Developing Erythroid Cells. J. Signal Transduction 2011, 1-7.
14. Hartenstein V. Blood cells and blood cell development in the animal kingdom. Annu. Rev. Cell. Dev. Biol. 2006, 22:677-712.
15. Jelkmann W. Regulation of erythropoietin production. J. Physiol. 2011, 589(Pt 6):1251.
16. Knight E., Eichenbaum G., Hillsamer V., Greway T., Tonelli A., Han-Hsu H., Zakszewski C., Yurkow E., Shukla U., End D., Louden C. Nonclinical safety assessment of a synthetic peptide thrombopoietin agonist: Effects on platelets, bone homeostasis, and immunogenicity and the implications for clinical safety monitoring of adverse bone effects. Int. J. Toxicol. 2011, 30:385-404.
17. Kondo M. Lymphoid and myeloid lineage commitment in multipotent hematopoietic progenitors. Immunol. Rev. 2010, 238(1):37.
18. Kraal G. Cells in the marginal zone of the spleen. Int. Rev. Cytol. 1992, 132:31-74.
19. Martin F., Kearney J.F. Marginal-zone B cells. Nat. Rev. 2002, 2:323-335.
20. Mebius R.E., Kraal G. Structure and function of the spleen. Nat. Rev. 2005, 5:606-616.
21. Orkin S.H., Zon L.I. Hematopoiesis: An Evolving Paradigm for Stem Cell Biology. Cell 2008, 132:631-644.
22. Schmidt E.E., MacDonald I.C., Grrom A.C. Comparative aspects of splenic microcirculatory pathways in mammals: the region bordering the white pulp. Scanning Microsc. 1993, 7:613-628.
23. Sonoda Y., Sasaki K. Surface morphology of the central macrophages of erythroblastic islets in the spleen of aged and pregnant mice: an immunohistochemical light microscopic study. Arch. Histol. Cytol. 2008, 71:155-161.
24. Travlos G.S. Normal structure, function, and histology of the bone marrow. Toxicol. Pathol. 2006, 34:548-565.
25. Terwilliger N.B. Functional adaptations of oxygen-transport proteins. J. Exp. Biol. 1998, 201(Pt 8):1085-1098.
26. Weiss D.J., Wardrop K.J. Schalm's Veterinary Hematology 2011, Wiley-Blackwell, New York, NY.
27. Cai S., Wang H., Bailey B., Ernstberger A., Juliar B.E., Sinn A.L., Chan R.J., Jones D.R., Mayo L.D., Baluyut A.R., Goebel W.S., Pollok K.E. Humanized Bone Marrow Mouse Model as a Preclinical Tool to Assess Therapy-Mediated Hematotoxicity. Clin. Cancer Res. 2011, 17(8):2195-2206.
28. Chen Y., Jacamo R., Shi Y.-X., Wang R.-Y., Battula V.L., Konoplev S., Strunk D., Hofmann N.A., Reinisch A., Konopleva M., Andreeff M. Human extramedullary bone marrow in mice: a novel in vivo model of genetically controlled hematopoietic microenvironment. Blood 2012, 119:4971-4980.
29. Cline J.M., Maronpot Robert R. Variations in histological distribution of bone marrow cells with respect to age and anatomic site. Toxicol. Pathol. 1985, 13:349-355.
30. Elmore S.E. Enhanced histopathology of the bone marrow. Toxicol. Pathol. 2006, 34(5):666-686.
31. Reagan W.J., Irizarry-Rovira Armando, Poitout-Belissent Florence, Bolliger Anne Provencher, Ramaiah Shashi K., Travlos Greg, Walker Dana, Bounous Denise, Walter Gail, Bone Marrow Working Group of ASVCP/STP Best practices for evaluation of bone marrow in nonclinical toxicity studies. Vet. Clin. Pathol. 2011, 40(2):119-135.
32. Risitano A.M. New challenges to developing animal models for human immune-mediated marrow failure. Clin. Med. Res. 2005, 3(2):63-64.
33. Scanu M., Mancuso L., Cao G. Evaluation of the use of human Mesenchymal Stem Cells for acute toxicity tests. Toxicol. In Vitro. 2011, 25(8):1989-1995.
34. Sharma M.B., Limaye L.S., Kale V.P. Mimicking the functional hematopoietic stem cell niche in vitro: recapitulation of marrow physiology by hydrogel-based three-dimensional cultures of mesenchymal stromal cells. Haematologica. 2012, 97(5):651-660.
35. Shenton J.M., Chen J., Uetrecht J.P. Animal models of idiosyncratic drug reactions. Chem. Biol. Interact. 2004, 150(1):53-70.
36. Travlos G. Normal structure, function and histology of the bone marrow. Toxicol. Pathol. 2006, 34(5):548-565.
37. Weiss D.J. Evaluation of proliferative disorders in canine bone marrow by use of flow cytometric scatter plots and monoclonal antibodies. Vet. Pathol. 2001, 38(5):512-518.
38. Weiss D.J. An indirect flow cytometric test for detection of anti-neutrophil antibodies in dogs. Am. J. Vet. Res. 2007, 68(5):464-467.
39. Weiss D.J., Wardrop K.J. Schalm's Veterinary Hematology 2011, Wiley-Blackwell, New York, NY.
40. Aster R.H., Bougie D.W. Drug-induced immune thrombocytopenia. N. Engl. J. Med. 2007, 357(6):580-587.
41. Bougie D.W., Wilker P.R., Aster R.H. Patients with quinine-induced immune thrombocytopenia have both "drug-dependent" and "drug-specific" antibodies. Blood 2006, 108(3):922-927.
42. Chen J. Bystander destruction of hematopoietic progenitor and stem cells in a mouse model of infusion-induced bone marrow failure. Blood 2004, 104(6):1671-1678.
43. Cuker A., CINES D.B. Immune thrombocytopenia. Hematology. Am Soc. Hematol. Educ. Prog. 2010, 2010:377-384.
44. Festing M.F.W., Diamanti P., Turton J.A. Strain differences in haematological response to chloroamphenicol succinate in mice: implications for toxicological research. Food Chem. Toxicol. 2001, 39(4):375-383.
45. George J.N., Aster R.H. Drug-induced thrombocytopenia: pathogenesis, evaluation, and management. Hematology. Am. Soc. Hematol. Educ. Prog. 2009, 2009(1):153-158.
46. Ghaffari S. Oxidative stress in the regulation of normal and neoplastic hematopoiesis. Antioxid. Redox Signal. 2008, 10(11):1923-1940.
47. Hole P.S., Pearn L., Tonks A.J., James P.E., Burnett A.K., Darley R.L., Tonks A. Ras-induced reactive oxygen species promote growth factor-independent proliferation in human CD34+ hematopoietic progenitor cells. Blood 2010, 115(6):1238-1246.
48. Inoue S., Noda S., Kashima K., Nakada K. Mitochondrial respiration defects modulate differentiation but not proliferation of hematopoietic stem and progenitor cells. FEBS lett. 2010, 584:3402-3409.
49. Jang Y.-Y., Sharkis S.J. A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 2007, 110(8):3056-3063.
50. Jardim D.L., Rodrigues C.A., Novis Y.A.S., Rocha V.G., Hoff P.M. xaliplatin-related thrombocytopenia. Ann. Oncol. 2012, (in press).
51. Kang K.-S., Trosko J.E. Stem cells in toxicology: fundamental biology and practical considerations. Toxicol. Sci. 2011, 120(Suppl. 1):S269-S289.
52. Konkle B.A. Acquired Disorders of Platelet Function. Hematology. Am. Soc. Hematol. Educ. Prog. 2011, 2011(1):391-396.
53. Kumar R., Crouthamel M.-C., Rominger D.H., Gontarek R.R., Tummino P.J., Levin R.A., King A.G. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 2009, 101(10):1717-1723.
54. Lang F., Qadri S.M. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood Purif. 2012, 33(1-3):125-130.
55. Lutz H.U. Naturally occurring anti-band 3 antibodies in clearance of senescent and oxidatively stressed human red blood cells. Transfus. Med. Hemother. 2012, 39:321-327.
56. Maiese K., Chong Z.Z., Hou J., Shang Y.C. Erythropoietin and oxidative stress. Curr. Neurovasc. Res. 2008, 5(2):125-142.
57. Mazharian A., Ghevaert C., Zhang L., Massberg S., Watson S.P. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 2011, 117(19):5198-5206.
58. McMichael M.A. Oxidative stress, antioxidants, and assessment of oxidative stress in dogs and cats. J. Am. Vet. Med. Assoc. 2007, 231(5):714-720.
59. Oldenborg P.-A. Role of CD47 and signal regulatory protein alpha (SIRPa) in regulating the clearance of viable or aged blood cells. Transfus. Med. Hemother. 2012, 39(5):315-320.
60. Olaharski A.J., Bitter H., Gonzaludo N., Kondru R., Goldstein D.M., Zabka T.S., Lin H., Singer T., Kolaja K. Modeling bone marrow toxicity using kinase structural motifs and the inhibition profiles of small molecular kinase inhibitors. Toxicol. Sci. 2010, 118(1):266-275.
61. Pervaiz S., Taneja R., Ghaffari S. Oxidative Stress Regulation of Stem and Progenitor Cells. Antioxid. Redox Signal. 2009, 11(11):2777-2789.
62. Poncin G., Beaulieu A., Humblet C., Thiry A., Oda K., Boniver J., Defresne M.P. Characterization of spontaneous bone marrow recovery after sublethal total body irradiation: importance of the osteoblastic/adipocytic balance. PLoS ONE 2012, 7(2). e30818.
63. Poulet F.M., Penraat K., Collins N., Evans E., Thackaberry E., Manfra D., Engstrom L., Geissler R., Geraci-Erck M., Frugone C., Abutarif M., Fine J.S., Peterson B.L., Cummings B.S., Johnson R.C. Drug-induced hemolytic anemia and thrombocytopenia associated with alterations of cell membrane lipids and acanthocyte formation. Toxicol. Pathol. 2010, 38(6):907-922.
64. Reese J.A., Li X., Hauben M., Aster R.H., Bougie D.W., Curtis B.R., George J.N., Vesely S.K. Identifying drugs that cause acute thrombocytopenia: an analysis using 3 distinct methods. Blood 2010, 116(12):2127-2133.
65. Russmann S., Grattagliano I., Portincasa P., Palmieri V.O., Palasciano G. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem. 2006, 13:3351-3357.
66. Schutz F.A.B., Je Y., Choueiri T.K. Hematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: A meta-analysis of clinical trials. Crit. Rev. Oncol. Hematol. 2011, 80(2):291-300.
67. Simsek T., Kocabas F., Zheng J., Deberardinis R.J., Mahmoud A.I., Olson E.N., Schneider J.W., Zheng C.C., Sadek H.A. The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche. Cell Stem Cell 2010, 7(3):380-390.
68. Tothova Z., Kollipara R., Huntly B., Lee B. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007, 128:325-339.
69. Tower J. Stress and stem cells. Wiley Interdisciplinary Rev. Dev. Biol. 2012, [Epub ahead of print].
70. Uetrecht J. Idiosyncratic drug reactions: past, present, and future. Chem. Res. Toxicol. 2008, 21(1):84-92.
71. Uetrecht J. Immune-mediated adverse drug reactions. Chem. Res. Toxicol. 2009, 22(1):24-34.
72. Weiss D.J. Cytologic evaluation of benign and malignant hemophagocytic disorders in canine bone marrow. Vet. Clin. Pathol. 2001, 30(1):28-34.
73. Weiss D.J. Acute bone marrow stromal injury in the dog. Comp. Clin. Path. 2007, 16(4):223-228.
74. Weiss D.J. Bone marrow pathology in dogs and cats with non-regenerative immune-mediated haemolytic anaemia and pure red cell aplasia. J. Comp. Pathol. 2008, 138(1):46-53.
75. Weiss D.J. Drug-associated blood cell dyscrasias. Compend. Contin. Educ. Vet. 2012, 34(6):E1-E8.
76. Zhang X., Zhang X., Liu F., Chen X., Zhu X., Uetrecht J. Involvement of the immune system in idiosyncratic drug reactions. Drug Metab. Pharmacokinet. 2011, 26(1):47-59.
77. Suttie Andrew W. Histopathology of the spleen. Toxicol. Pathol. 2006, 34(5):466-503.
78. Frith C.H., Ward J.M., Tyler R.D., Chandra M., Stromberg P.C. Proliferative lesions of the hematopoietic and lymphatic systems in rats, HL-1, in Guides for Toxicologic Pathology 1996, STP/ARP/AFIP, Washington DC, pp 1-20. https://www.toxpath.org/ssdnc/hemolyphaticproliferativeR.pdf.
79. Frith C.H., Ward J.M., Chandra M., Losco P.E. Non-proliferative lesions of the hematopoietic system in rats, HL-1, in Guides for Toxicologic Pathology 2000, STP/ARP/AFIP, Washington DC, pp 1-22. https://www.toxpath.org/ssdnc/hematopoieticnonprolifrat.pdf.
80. Jain N.C. Depression or hypoproliferative anemias. Schalm's Veterinary Hematology 1986, Lea and Febiger, Philadelphia, PA, 655-675. fourth ed.
81. MacKenzie W.F., Eustis S.L. Bone marrow. Pathology of the Fischer Rat 1990, 395-403. Academic Press, Inc., San Diego, CA. G.A. Boorman, S.L. Eustis, M.R. Elwell, C.A. Montgomery, W.F. MacKenzie (Eds.).
82. Meierhenry E.F. Literature Review - The effects of inanition on rat bone marrow, Society of Toxicologic Pathologists Great Lakes Region Discussion Group: Bone Marrow Toxicity. Toxicol. Pathol. 1990, 18:707-708.
83. Mintzer D.M., Billet S.N., Chmielewski L. Drug-induced hematologic syndromes. Adv. Hematol. 2009, 2009:1-11.
84. Reagan W.J. A review of myelofibrosis in dogs. Toxicol. Pathol. 1993, 21:164-169.
85. Travlos G.S. Histopathology of bone marrow. Toxicol. Pathol. 2006, 34:566-598.
86. Valli V.E., McGrath J.P., Chu I. Hematopoietic System. Handbook of Toxicologic Pathology 2002, 647-679. Academic Press, San Diego CA. second ed. W.M. Haschek, C.G. Rousseaux, M.A. Wallig (Eds.).
87. Waner T., Harrus S. Anemia of Inflammatory Disease. Schalm's Veterinary Hematology 2000, 205-209. Lippincott, Williams and Wilkins, Philadelphia, PA. fifth ed. B.F. Feldman, J.G. Zinkl, N.C. Jain (Eds.).
88. Weiss D.J. Bone marrow necrosis in dogs: 34 cases (1996-2004). J. Am. Vet. Med. Assoc. 2005, 227(2):263-267.
89. Weiss D.J. Recognition and classification of dysmyelopoiesis in the dog: a review. J. Vet. Intern. Med. 2005, 19(2):147-154.
90. Weiss D.J. A retrospective study of the incidence and the classification of bone marrow disorders in the dog at a veterinary teaching hospital (1996-2004). J. Vet. Intern. Med. 2006, 20(4):955-961.
91. Weiss D.J. Acute bone marrow stromal injury in the dog. Comp. Clin. Pathol. 2007, 16(4):223-228.